World of DTC Marketing

APRIL 22, 2021

QUICK READ: More TV DTC spots are airing, but DTC marketers are losing the battle between awareness and conversion because of all the noise online. I’ve spent the last six months analyzing clients’ DTC marketing campaigns and they are, for most ineffective.

Marketing 265

Marketing Doctors Doctor Production 265

Pharmaceutical Technology

MARCH 28, 2023

Following on from its Covid-19 vaccine programmes, BioNTech has set its sights on a range of infectious diseases for vaccine development. The company saw major successes with its Covid-19 vaccine, developed in collaboration with Pfizer. In response to the lower vaccine sales forecasts, BioNTech shares opened at 3.9%

Vaccine 276

Vaccine Vaccination Development Clinical Trials 276

Bio Pharma Dive

FEBRUARY 13, 2023

The company said its modified contract with the federal government, which comes ahead of a planned transition to private market sales, will help it develop an updated version of its vaccine.

Sales 342

Sales Vaccine Vaccination Marketing 342

Pharmaceutical Technology

JUNE 28, 2022

Astellas Pharma and Sutro Biopharma have entered a global, strategic partnership and licencing agreement to discover and develop new immunostimulatory antibody-drug conjugates (iADCs). Astellas and Sutro will expedite the development of iADCs for three different biological targets. It can potentially enhance the anti-cancer effect.

Development 264

Development Antibody Immune Response Production 264

World of DTC Marketing

NOVEMBER 16, 2021

SUMMARY: Omnichannel marketing employs the simultaneous implementation of channels across personal, non-personal, and media and addresses the integrated needs of multiple stakeholders – consumers/patients, healthcare professionals, and payers. Today there are microsegments of markets, and one message shouldn’t be used for all.

Marketing 253

Marketing Doctors Doctor Sales 253

Pharmaceutical Technology

JULY 13, 2022

Merck (MSD outside North America) and Orion have entered an international agreement to develop and market the latter’s investigational candidate ODM-208 to treat metastatic castration-resistant prostate cancer (mCRPC). Orion discovered and developed ODM-208 to treat hormone-dependent cancers, such as prostate cancer.

Development 264

Development Hormones Production Marketing 264

Pharmaceutical Technology

DECEMBER 15, 2022

Eisai has entered a comprehensive research partnership agreement with Washington University School of Medicine in St Louis, US, to develop potential new therapies for neurodegenerative ailments. Under the deal, the parties intend to develop treatments for diseases including Alzheimer’s and Parkinson’s.

Development 246

Development Medicine Sales Scientist 246

Pharmaceutical Technology

JULY 26, 2022

According to GlobalData’s recent Niemann-Pick Type C (NPC): Opportunity Analysis and Forecast to 2031 report, the NPC market is expected to see significant growth during 2021–31. This sales growth will be in line with a steadily increasing disease prevalence and the entrance of novel agents into the market.

Marketing 306

Marketing Gene Branding Clinical Development 306

Pharmaceutical Technology

MAY 26, 2023

The immuno-oncology market continues to evolve as treatments establish their presence across different types of cancer, having seen approvals in multiple indications in the past decade. These figures are only expected to grow in the coming years, with sales forecasted to reach over $150 billion by 2028.

Marketing 264

Marketing Vaccine Vaccination Development 264

Pharmaceutical Technology

DECEMBER 12, 2022

Gilead company Kite has entered an international strategic partnership with Arcellx for the joint development and commercialisation of the latter’s T-cell therapy, CART-ddBCMA, to treat relapsed or refractory multiple myeloma patients. Additionally, Kite will make other potential payments to Arcellx.

Development 264

Development Gene Therapy Clinical Trials Clinical Trials 264

World of DTC Marketing

APRIL 6, 2022

DTC marketing has evolved. Challenge #1 – DIGITAL MARKETING. Pharma companies are increasing digital budgets, but they are wasting too much money because of internal staffing issues and inexperience with online marketing. Paid Media – The most commonly used KPI in marketing is essentially worthless.

Marketing 196

Marketing Sales Pharma Companies Doctors 196

Bio Pharma Dive

MARCH 15, 2022

Instead of sharing global profits and losses, Eisai will receive royalties tied to net sales of the Alzheimer's drug. Biogen, meanwhile, said the amended deal should make it easier to "address market developments."

Sales 152

Sales Marketing Development Drugs 152

Pharmaceutical Technology

JANUARY 25, 2023

It was an exceptional year for Moderna’s vaccine Spikevax, with forecast sales of $19.5bn in 2022. Currently, Spikevax is the second bestselling Covid-19 vaccine behind Pfizer’s Comirnaty, which is in the leading position, with forecast sales of $37bn in 2022.

Sales 147

Sales Vaccine Vaccination Marketing 147

Pharma Mirror

JUNE 23, 2023

In the fast-paced, highly competitive pharmaceutical industry, sales reps must adapt to new ways of engaging with customers and healthcare professionals (HCPs).

Sales 130

Sales Development Marketing 130

Pharmaceutical Technology

FEBRUARY 8, 2023

The top 20 companies in the global biopharma industry saw 5.4%* aggregate market capitalization from $3.43 Pfizer maintained its third-place position in the market in 2022, reporting a market capitalization of $287.6 witnessed the biggest market capitalization growth of 45.3% trillion to $3.61 billion on Dec 31, 2022.

Marketing 195

Marketing Sales Vaccine Vaccination 195

pharmaphorum

NOVEMBER 19, 2021

The race to find and bring vaccines to market to fight Covid was impressive. So too are the sales figures. The mRNA jab, developed by Pfizer and BioNTech, launched to huge fanfare in December 2020 and promised the start of the end of the coronavirus pandemic. Pfizer/BioNTech’s vaccine dominates the market.

Sales 137

Sales Vaccine Vaccination Marketing 137

Drug Patent Watch

JANUARY 30, 2025

Maximizing Patent Protection: Strategies for Pharmaceutical Marketers As a pharmaceutical marketer, you know how crucial it is to protect your patented drug's market share. In this post, we'll explore effective strategies for maximizing patent protection and exclusivity, ensuring your product remains a leader in the market.

Marketing 59

Marketing Drugs Production Sales 59

Pharma Marketing Network

MARCH 26, 2025

Artificial intelligence (AI) is no longer a futuristic concept in healthcareits here, embedded in nearly every touchpoint of modern pharma marketing. But as pharma marketers race to adopt these tools, a central question looms: Is AI fueling smarter engagement, or setting the stage for a compliance disaster?

Compliance 64

Compliance Marketing Regulation Pharma Companies 64

Camargo

NOVEMBER 11, 2020

Each month, Camargo’s “In the News” series highlights important changes and advancements in the regulatory and development space and explores how those changes could impact your program. Presumably, Antares’ long-established 90-person urology sales force can achieve pull-thru of this drug product. Manager of Regulatory Compliance.

Development 242

Development Bioequivalency Generic Drugs Production 242

Pharmaceutical Technology

AUGUST 30, 2022

International companies investing in the emerging market of Brazilian pharmaceutical manufacturing will see a higher return on investment than from developed market equivalents, if they choose to compete with local manufacturers to supply Brazil’s growing market and the greater South American region.

Manufacturing 195

Manufacturing Marketing Pharma Companies Vaccine 195

Pharmaceutical Technology

DECEMBER 15, 2022

In an expanded version of the sales forecast from GlobalData’s June 2022 publication, Cardiomyopathies: Global Drug Forecast and Market Analysis , the global cardiomyopathies market is expected to grow from $3.07bn last year to $9.63bn in 2031. of sales in 2021 and 2031 respectively.

Marketing 130

Marketing Sales Clinical Trials Clinical Trials 130

Pharma Marketing Network

JULY 19, 2023

Content Marketing as a Sales Driver: Unlocking Your Business Potential in the Pharmaceutical Industry Content marketing is a long-term strategy that can help businesses of all sizes generate leads, increase brand awareness, and drive sales.

Sales 98

Sales Marketing Branding Production 98

Pharmaceutical Technology

DECEMBER 14, 2022

GSK has entered a strategic partnership with Wave Life Sciences to progress the discovery and development of oligonucleotide therapies for new genetic targets. The discovery alliance, with a preliminary research period of four years, will aid GSK in progressing up to eight programmes and Wave to develop up to three programmes.

Life Science 162

Life Science Development Gene Therapy Genetics 162

World of DTC Marketing

OCTOBER 5, 2021

last year gave away more than $23 billion in rebates to insurance intermediaries, but still netted $50 billion in sales. This taxpayer support comes during the riskiest and most pivotal points in early drug discovery, whereas private funding often comes in later to support development and regulatory approval. Washington Post.

Sales 241

Sales Drugs Manufacturing Production 241

Pharmaceutical Technology

DECEMBER 19, 2022

With the latest development, Sanofi will licence a NK cell engager programme that acts on B7H3 from the antibody-based NK cell engager therapeutics (ANKET) platform of Innate. On choosing the candidate, the company will oversee the complete development, production and marketing.

Development 264

Development Engineer Clinical Trials Clinical Trials 264

Pharmaceutical Technology

MAY 8, 2023

Shanghai Junshi Biosciences and Dr. Reddy’s Laboratories have partnered for the development and commercialisation of the anti-PD-1 monoclonal antibody, toripalimab, in 21 countries. upfront payment, potential expansion of Dr. Reddy’s Territory and milestone payment, along with royalties on the net sales of the products comprising toripalimab.

Development 130

Development Marketing Licensing Licensing 130

Pharmaceutical Technology

AUGUST 4, 2022

Poseida Therapeutics and Roche have signed a strategic partnership and licence agreement to develop allogeneic CAR-T cell therapies for hematologic malignancies. Roche and Poseida will also partner in a research programme for creating and developing next-generation features and enhancements for allogeneic CAR-T therapies.

Development 147

Development Clinical Trials Clinical Trials Gene Therapy 147

Pharmaceutical Technology

MAY 30, 2023

Lecanemab by Eisai Co Ltd, a monoclonal antibody therapy marketed for Alzheimer’s disease, is predicted to achieve the most significant commercial debut. Lecanemab leads the charge with projected sales of $4.67bn in 2028, 529% more than its closest competitor, Gammagard by Takeda. Similarly, Almirall S.A.,

Drugs 264

Drugs Sales Antibody Dermatology 264

Pharmaceutical Technology

JUNE 12, 2023

Accordingly, the development of non-opioid painkillers is experiencing a surge in activity and despite numerous novel targets receiving high levels of attention, cannabinoids have emerged as strong favourites to replace opioid-related medications. On 9 May, National Fentanyl Awareness Day was observed in recognition of the US opioid crisis.

Drugs 358

Drugs Development Clinical Development Sales 358

Pharmaceutical Technology

AUGUST 30, 2022

Zerion Pharma has entered a partnership with Insud Pharma for the development and marketing of drug products using Zerion Pharma's solubility-boosting Dispersome technology. . Under the deal, Zerion will handle the development of Dispersome formulations of marketed drugs.

Development 130

Development Drugs Bioavailability Production 130

Pharmaceutical Technology

DECEMBER 23, 2022

Merck (MSD outside North America) has signed an exclusive licence and partnership agreement with Kelun-Biotech for developing seven investigational preclinical antibody-drug conjugates (ADC) to treat cancer. Kelun-Biotech is entitled to get payments of up to $9.3bn in the future on meeting development, regulatory and sales milestones.

Development 130

Development Sales Production Antibody 130

XTalks

NOVEMBER 21, 2024

Additionally, over a 176-week period, weekly injections of tirzepatide (marketed as Zepbound and Mounjaro) using pooled doses of 5 mg, 10 mg and 15 mg, significantly reduced the risk of disease progression to type 2 diabetes by 94 percent compared with placebo in adult prediabetes patients who were obese or overweight.

Sales 105

Sales Insulin Drugs Trials 105

Pharmaceutical Technology

OCTOBER 31, 2022

The osteoarthritis (OA) market was valued at $2.5 billion in the 7MM (seven major markets) in 2021, and is expected to increase to $3.8 These are forecast to contribute significantly towards sales in the OA market in 2031, accounting for 10% and 14.2% of the 7MM sales, respectively. in the US).

Marketing 147

Marketing Sales Clinical Trials Clinical Trials 147

Pharmaceutical Technology

JULY 28, 2022

Notable key players in the NSAID OA market are Novartis with Voltaren (diclofenac) and Bayer with naproxen. Eli Lilly is another key player in the OA market due to duloxetine. But while these products will continue to play a role in the OA treatment market, continued sales erosion is expected due to generics.

Marketing 130

Marketing Generic Pharmaceutical Sales Production 130

Pharmaceutical Technology

DECEMBER 16, 2022

The endometriosis market is expected to grow from $1.05bn in 2020 to $2.72bn in 2030 at a compound annual growth rate (CAGR) of 10.0% The endometriosis market is expected to grow from $1.05bn in 2020 to $2.72bn in 2030 at a compound annual growth rate (CAGR) of 10.0% of 7MM sales.

Marketing 147

Marketing Hormones Sales Branding 147

Pharmaceutical Technology

MAY 16, 2023

More than half of the top 20 global biopharmaceutical companies saw a fall in market capitalisation over Q1 2023. decline in total aggregate market capitalisation from $3.61 Bayer reported the highest market capitalisation growth of 23.1% Sanofi and Regeneron’s market capitalisation grew by 12.4% This resulted in a 3.4%

Marketing 130

Marketing Sales Generic Drugs Vaccination 130

Pharmaceutical Technology

OCTOBER 28, 2022

On 24 October, American vaccine developer Vaxcyte shared positive topline data from a Phase I/II study of its multivalent conjugate pneumococcal vaccine VAX-24 , bringing the 24-valent pneumococcal jab one step closer to market. VAX-24 has forecasted sales of $21 million in the same year. billion and $812 million in 2028.

Vaccine 162

Vaccine Vaccination Marketing Bacteria 162